Skip to main content
. 2022 Feb 25;19(2):476–490. doi: 10.1007/s13311-022-01202-1

Fig. 5.

Fig. 5

Treatment discontinuation rates (A) and cumulative probabilities (B) with their 95% confidence interval according to the time since treatment initiation obtained from modeling in the natalizumab and anti-CD20 groups. Abbreviations: NTZ, natalizumab